$0.12
(Market cap
$1,672 Mln
Recently Viewed
Clear AllMarket cap
$1,672 Mln
Revenue (TTM)
$69 Mln
P/E Ratio
--
P/B Ratio
2.2
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.9
Debt to Equity
0.2
Book Value
$5.5
EPS
$-3.2
Face value
--
Shares outstanding
161,234,058
CFO
$355.83 Mln
EBITDA
$729.22 Mln
Net Profit
$-229.72 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vir Biotechnology (VIR)
| 74.0 | 17.1 | 40.9 | 71.5 | -24.6 | -27.1 | -- |
|
BSE Sensex
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Vir Biotechnology (VIR)
| -17.8 | -26.9 | -60.3 | -39.6 | 56.3 | 113.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vir Biotechnology (VIR)
|
10.5 | 1,672.0 | 68.6 | -438.0 | -675.6 | -45.7 | -- | 2.2 |
| 73.8 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 65.0 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 45.5 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 90.0 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 66.1 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 512.8 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 415.4 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 105.2 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 341.0 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of... product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. Read more
Executive VP & Chief Technology Officer
Dr. Ann M. Hanly Ph.D.
Executive VP & Chief Technology Officer
Dr. Ann M. Hanly Ph.D.
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Vir Biotechnology Inc (VIR) is $10.49 (NASDAQ) as of 27-Apr-2026 10:37 EDT. Vir Biotechnology Inc (VIR) has given a return of -24.57% in the last 3 years.
Since, TTM earnings of Vir Biotechnology Inc (VIR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.91
|
1.10
|
|
2024
|
-1.91
|
0.87
|
|
2023
|
-2.19
|
0.85
|
|
2022
|
6.62
|
1.64
|
|
2021
|
10.54
|
3.89
|
The 52-week high and low of Vir Biotechnology Inc (VIR) are Rs 11.50 and Rs 4.16 as of 27-Apr-2026.
Vir Biotechnology Inc (VIR) has a market capitalisation of $ 1,672 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vir Biotechnology Inc (VIR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.